Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Embecta Corp. securities between November 25, 2025 and May 4, 2026. The complaint alleges that Embecta misled investors by providing overly optimistic revenue guidance and reaffirming strength in its pen needle segment. On May 5, 2026, Embecta reported second quarter fiscal 2026 results showing a revenue decline of over 14%, far worse than its guidance of flat to a 2% decline, and lowered its full-year outlook, citing weakness in pen needle sales. Following the news, Embecta's stock price fell to $3.90 per share. Shareholders who wish to serve as lead plaintiff must contact Robbins LLP before the deadline.
Embecta CorpClass action lawsuit filed over alleged misleading guidance, causing stock price drop.